Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Credit agrmnt [a]
Appointed director
Pfenex Inc. (PFNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/01/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/26/2020 8-K Quarterly results
06/12/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States • The first FDA-approved teriparatide with Forteo® 1-3 as the reference drug SAN DIEGO, June 12, 2020 —Pfenex Inc. today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States. Teriparatide Injection is a prescription medicine approved for several uses, including in postmenopausal women with osteoporosis who are at high risk for having bone fractures. Teriparatide Injection is the first teriparatide product since Forteo® 1-3 approved for this use. The Alvogen product is pharmaceutically equivalent to Forteo and has been shown to have comparable bioavailability. These characteristics allowed the product to be approved ..."
05/11/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : May 8, 2020 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act )..."
05/07/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
04/23/2020 8-K Entry into a Material Definitive Agreement, Other Events
Docs: "Q"
04/14/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence Determination FDA review for a Therapeutic Equivalency rating for PF708 continues"
03/11/2020 8-K Quarterly results
02/04/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : February 3, 2020 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange ..."
01/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : January 14, 2020 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange ..."
12/18/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : December 18, 2019 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange...",
"Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals"
11/13/2019 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Pfenex Reports Third Quarter 2019 Results and Provides Business Update Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo®"
10/15/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : October 14, 2019 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange ...",
"Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study"
10/07/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : October 7, 2019 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange A...",
"Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis - - -"
08/08/2019 8-K Quarterly results, Resignation/termination of a director
Docs: "Pfenex Reports Second Quarter 2019 Results and Provides Business Update",
"About Pfenex Inc."
05/09/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated 2014 Equity Incentive Plan and forms of award thereunder",
"Amended and Restated 2014 Equity Incentive Plan and forms of award thereunder"
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : May 9, 2019 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act )...",
"Pfenex Reports First Quarter 2019 Results and Provides Business Update"
04/01/2019 8-K Other Events
03/11/2019 8-K Quarterly results
Docs: "Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update"
03/04/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : February 28, 2019 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange...",
"About Pfenex Inc."
02/28/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
01/22/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : January 17, 2019 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange ..."
12/10/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis Submitted as a 505 NDA with an Expected Ten-Month Review SAN DIEGO, December 10, 2018— Pfenex Inc. today announced the submission of its New Drug Application to the U.S. Food and Drug Administration seeking approval of PF708 for the treatment of osteoporosis. The application is submitted as a 505 NDA and references Eli Lilly and Company's Forteo ® as the Reference Listed Drug. “We are pleased to submit to the FDA an NDA for PF708 as a proposed therapeutic equivalent to Forteo ® , which achieved $1.7 billion in global sales in 2017,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “We believe the timing of the NDA submission for PF708 could allow for a potential commercia..."
11/07/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation"
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : November 7, 2018 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange ...",
"Pfenex Reports Third Quarter Results and Provides Business Update"
09/11/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement, effective October 1, 2018, between the Company and Shawn A. Scranton, PharmD",
"Pfenex Names Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer SAN DIEGO, September 11, 2018 —Pfenex Inc. today announced that Dr. Shawn A. Scranton, will be joining Pfenex as its Chief Operating Officer, effective October 1, 2018. “As our operations have evolved through the advancement of our clinical pipeline and Pfenex is working towards its first NDA submission, we are increasing our focus on the approval and commercialization of our existing pipeline as well as exploration of new pipeline and technology opportunities. I am excited to announce the appointment of Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer, who will support this transition to a commercial stage biotech company” said Eef Schimmelpennink, Chief Executive Officer of Pfenex...."
08/16/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : August 16, 2018 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange A...",
"Pfenex Announces Departure of Chief Medical and Scientific Officer Dr. Hubert Chen SAN DIEGO, August 16, 2018 — Pfenex Inc. announced today that Dr. Hubert Chen has resigned from his role as Chief Medical and Scientific Officer, effective September 2, 2018, but will continue to support the company as an advisor. The company is conducting a search for a successor. “We appreciate Dr. Chen's contributions to Pfenex and his work with the scientific team in the advancement of our portfolio of clinical assets, including our lead asset, PF708, a therapeutic equivalent to Forteo ® ,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “As we announced previously, following our pre-NDA meeting, we believe the U.S. Food and Drug Administration supports our strategy for filing the new drug a..."
08/08/2018 8-K Quarterly results
Docs: "PFENEX INC. Consolidated Statements of Operations"
06/11/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a Therapeutic Equivalent Candidate to Forteo ®"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy